Jobs
-
The UK’s National Institute for Health Care and Excellence (NICE) has issued a new “patient decision aid” that emphasizes that a metered dose inhaler “contains propellant, so it has a higher carbon footprint than a… Read more . . .
-
Endo International has announced that its subsidiary Endo Procurement Operations Limited recently reached an agreement with Merck to distribute an authorized generic of Proventil HFA albuterol sulfate MDI in the US. Endo operating company Par… Read more . . .
-
According to Evoke Pharma, the FDA has issued a complete response letter in response to the company’s NDA for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis. The PDUFA date for completion of… Read more . . .
-
Finnish particle engineering company Nanoform has named former Hovione executive Miguel Calado as Vice Chairman of the Board. In addition to having served as CFO and VP of Finance of Hovione, Calado has also been… Read more . . .
-
Opiant Pharmaceuticals has received an additional $3 million from a 3-year grant awarded in 2018 by the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) to support development of OPNT003 intranasal nalmefene… Read more . . .
-
Pulmatrix announced that it has signed an agreement with Cipla subsidiary Cipla Technologies (Cip Tec) that “lays the groundwork” for Cip Tec to acquire the rights to Pulmazole (PUR1900) inhaled dry powder itraconazole for the… Read more . . .
-
MannKind Corporation has announced that it has received a $12.5 million milestone payment from United Therapeutics for the first milestone related to development of a treprostinil Technosphere (TreT) DPI for the treatment of pulmonary arterial… Read more . . .
-
3M Drug Delivery Systems will officially open a new 1,300 sq m R&D Inhalation Centre of Excellence on is Charnwood Campus in Loughborough, UK this month, the company said. According to 3M DDS, the new… Read more . . .
-
VistaGen Therapeutics has presented new data from a Phase 3 study of PH94B nasal spray for the treatment of social anxiety disorder (SAD) at the 2019 Anxiety and Depression Association of America (ADAA) Annual Conference.… Read more . . .
-
Savara has announced the initiation of the Phase 2a ENCORE study of its Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection in cystic fibrosis patients. The… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland